BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A
BlackRock Portfolio Management LLC has filed an amendment to a Schedule 13G/A, indicating beneficial ownership of 2,508,488 shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), which represents 4.2% of the class. The filing specifies that BlackRock holds sole voting power over 2,206,827 shares and sole dispositive power over 2,508,488 shares. This passive institutional holding is below the 5% threshold typically associated with activist investor signaling.
APR 23·Minichart▲
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to Board of Directors to Drive Growth and Innovation in CNS Therapies 1
Vanda Pharmaceuticals Inc. has appointed Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. Dr. Duncan brings over 30 years of experience in the life sciences and biotechnology sector, particularly in neurology and psychiatry, and his appointment is expected to bolster Vanda's strategic growth and innovation in CNS therapies. This move, alongside recent product approvals and a robust pipeline, positions Vanda for a new era of growth, although investors are cautioned about inherent risks.
APR 3·TipRanks→
Vanda Announces Resignation of Senior Legal Executive
Vanda Pharmaceuticals announced the resignation of Timothy Williams, its Senior Vice President, General Counsel, and Secretary, effective April 10, 2026. This departure marks a significant change in the company's executive legal leadership, potentially impacting its corporate governance and strategic matters. The company's stock currently has a Hold rating with a $7.00 price target from analysts, while TipRanks' AI Analyst Spark rates VNDA as Neutral due to weak financial performance despite strong technical momentum.
